| 764658 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
476 First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results |
2021-11-01 |
10.1136/jitc-2021-sitc2021.476 |
Dudek Arkadiusz, Juric Dejan, Dowlati Afshin, Vaishampayan Ulka, Assad Hadeel, Rodón Jordi, Chao Bo, Wang Bingxia, Gibbs John, Shinde Vaishali, Friedlander Sharon, Berger Allison, Ward Christine, Martinez Alonzo, Gharavi Robert, Gomez-Pinillos Alejandro, Proscurshim Igor, Olszanski Anthony |
| 764657 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
475 GEN-011–101 (the TiTAN-1 trial): phase 1 study to evaluate the safety, proliferation and persistence of GEN-011, an autologous neoantigen-targeted peripheral T cell therapy in solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.475 |
Davis Thomas, DeCillis Arthur, Hernandez Richard, Price Jessica, Carey Craig, Mancini Kevin |
| 764656 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.474 |
Davar Diwakar, Ribrag Vincent, Sarkozy Clementine, Garralda Elena, Oberoi Honey Kumar, Mehta Amitkumar, Curigliano Giuseppe, Belli Carmen, Zain Jasmine, Herrera Alex, Sanborn Rachel, Dumbrava Ecaterina, Forero-Torres Andres, Ansell Stephen |
| 764655 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
473 Immune profiling of patients with advanced solid tumors treated with intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in phase I clinical trial |
2021-11-01 |
10.1136/jitc-2021-sitc2021.473 |
Codó Paula, Eigentler Thomas, Heinzerling Lucie, Krauss Juergen, Weishaupt Carsten, Ochsenreither Sebastian, Lebbe Celeste, Mohr Peter, Oliva Marc, Oberoi Honey, Terheyden Patrick, Pérez José Trigo, Bauernfeind Franz-Georg, Fluck Michael, Richtig Erika, Soria Ainara, Gonzalez Marina, Funkner Fatma, Wengenmayer Peter, Vahrenhorst Dominik, Seibel Tobias, Quintini Gianluca, Schmitt-Bormann Beate, Scheel Birgit, Falk Martin, Gnad-Vogt Ulrike |
| 764654 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
349 Tolerability of tivozanib vs. sorafenib in elderly and/or immunotherapy-pretreated patients with metastatic renal cell cancer (mRCC) in TIVO-3 |
2021-11-01 |
10.1136/jitc-2021-sitc2021.349 |
Kasturi Vijay, Escudier Bernard, Rini Brian, Pal Sumanta, McDermott David, Porta Camillo, Verzoni Elena |
| 764653 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
348 Interleukin 2(IL-2) systems immunology modeling: machine learning for cancer immunotherapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.348 |
Bone Jennifer, Washburn Newell, Han Jian, Steele Miranda, Murthy Pranav, Lotze Michael |
| 764652 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of 22 months of follow-up |
2021-11-01 |
10.1136/jitc-2021-sitc2021.347 |
Appleman Leonard, Todenhoefer Tilman, Berry William, Gurney Howard, Retz Margitta, Conter Henry, Laguerre Brigitte, Fong Peter, Ferrario Cristiano, Gravis Gwenaelle, Piulats Josep, Emmenegger Urban, Shore Neal, Romano Emanuela, Mourey Loic, Li Xin Tong, Poehlein Christian, Schloss Charles, Bono Johann De, Yu Evan |
| 764651 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
345 Phase I/II trial of cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies (CAMILLA): phase Ib safety and efficacy results |
2021-11-01 |
10.1136/jitc-2021-sitc2021.345 |
Saeed Anwaar, Park Robin, Dai Junqiang, Al-Rajabi Raed, Kasi Anup, Baranda Joaquina, Williamson Stephen, Collins Zachary, Ripp Jacob, Saeed Azhar, Mulvaney Kelly, Manirad Vanna, Madan Rashna, Subramaniam Dharmalingam, Anant Shrikant, Phadnis Milind, Sun Weijing |
| 764650 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
344 Avelumab + binimetinib in metastatic pancreatic ductal adenocarcinoma (mPDAC): dose-escalation results from the phase 1b/2 JAVELIN PARP MEKi trial |
2021-11-01 |
10.1136/jitc-2021-sitc2021.344 |
Rodon Jordi, Tan Daniel Weng, Laguna Ignacio Garrido, Harb Wael, Thaddeus Beck J, Bahary Nathan, Rottey Sylvie, Zhu Zhou, Deng Shibing, Kowalski Karen, O’Neill Grainne, Wei Caimiao, Pathan Nuzhat, Messersmith Wells |
| 764649 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
342 Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/activation in patients with microsatellite-stable/instability-low metastatic colorectal cancer in a phase 1 study |
2021-11-01 |
10.1136/jitc-2021-sitc2021.342 |
Krige David, Fakih Marwan, Rosen Lee, Wang Ding, Harb Wael, Babiker Hani, Berlin Jordan, Genova Gianfranco Di, Miles David, Powell Mark, Patel Minesh, Carter Jo, Brown Richard, Lillie Tom |
